<DOC>
	<DOCNO>NCT00192374</DOCNO>
	<brief_summary>- Trial Compare Safety , Tolerability , Immunogenicity Efficacy Three Dose Levels Liquid Formulation ( CAIV-T ) Healthy Children .</brief_summary>
	<brief_title>Trial Compare Safety , Tolerability , Immunogenicity Efficacy Three Dose Levels Liquid Formulation Influenza Virus Vaccine , ( CAIV-T ) Healthy Children</brief_title>
	<detailed_description>- A Prospective , Randomized , Double-Blind , Placebo-Controlled , Phase III , Multicenter Trial Compare Safety , Tolerability , Immunogenicity Efficacy Three Dose Levels Liquid Formulation Influenza Virus Vaccine , Trivalent , Types A &amp; B , Live Cold-Adapted ( CAIV-T ) Healthy Children</detailed_description>
	<criteria>•who age least 6 month le 36 month age time first vaccination good health determine medical history , physical examination clinical judgement whose parent ( ) /legal guardian ( ) provide write informed consent nature study explain , along parent ( ) /legal guardian ( ) , available duration trial ( 8 month ±1 month ) whose parent ( ) /legal guardian ( ) , reach study staff postvaccination contact [ telephone , clinic home visit ] . whose parent ( ) /legal guardian ( ) perceive unavailable difficult contact evaluation study visit study period serious chronic disease ( e.g. , sign cardiac renal failure severe malnutrition ) , include progressive neurological disease Down 's syndrome know cytogenetic disorder know suspected disease immune system receive immunosuppressive therapy , include systemic corticosteroid ( see Section 4.2.1 ) receive blood product , include immunoglobulin , period six month prior vaccination conclusion study intent administer investigational vaccine agent one month prior enrollment conclusion study immunosuppressed immunocompromised individual living household , time prior entry study , receive dose influenza vaccine ( commercial investigational ) document history hypersensitivity egg egg protein component assign study vaccine receive aspirin ( acetylsalicylic acid ) aspirincontaining product two week prior vaccination use anticipate study medical condition opinion investigator might interfere interpretation study result . If criterion meet follow enrolment , subject exclude subsequent vaccine dosing . Note : Pregnancy household member person regular contact subject contraindication enrollment ongoing participation subject study .</criteria>
	<gender>All</gender>
	<minimum_age>6 Months</minimum_age>
	<maximum_age>35 Months</maximum_age>
	<verification_date>October 2006</verification_date>
</DOC>